In vitro fertility describes medical procedures that combine egg and sperm outside the body to create embryos that can be implanted to achieve pregnancy. Think of it like a controlled nursery where early stages of conception are managed to improve chances of success; investors care because demand, costs, success rates, regulation, and technological advances in these services affect revenues and growth potential for clinics, drugmakers, and medical-device suppliers.
embryo transfermedical
Embryo transfer is the medical step in fertility treatment where an embryo is placed into a person’s uterus so it can implant and develop, like planting a seed in a garden and hoping it takes root. For investors, it’s the critical outcome-driven moment that determines clinic success rates, revenue from procedures and demand for related drugs, devices and diagnostics, and it often faces regulatory and reimbursement scrutiny that affects company value.
cryopreservationmedical
Cryopreservation is the process of freezing biological materials—such as cells, tissues, blood, vaccines or embryos—at very low temperatures to halt chemical activity and preserve them for future use. For investors, it matters because reliable freezing affects a biotech or healthcare company’s ability to store and transport products, preserve research assets, extend shelf life, meet regulatory requirements, and scale manufacturing; failures can cause product loss, costly delays, or regulatory risks much like a spoiled freezer full of perishable goods.
colony rederivationmedical
Colony rederivation is a laboratory process used to create a new, disease-free breeding group of research animals (most often mice) by transferring embryos or newborns into pathogen-free surrogate mothers. For investors, it matters because it preserves the integrity and reproducibility of preclinical studies, avoids costly delays from contamination or regulatory setbacks, and can require significant time and expense—like rebuilding a clean factory line to ensure reliable product testing.
genetic validationmedical
Genetic validation is the process of confirming that a specific gene or genetic change actually causes or influences a disease, making it a credible target for a drug or diagnostic. For investors, it matters because treatments backed by genetic evidence are more likely to succeed in development—think of it as checking the blueprints before building; validated targets reduce scientific risk, inform trial design, and can increase the value and attractiveness of biotech investments.
assisted reproduction techniquemedical
A set of medical methods that help people have children when natural conception is difficult, using clinical procedures to handle eggs, sperm or embryos and assist fertilization and pregnancy. Investors watch these techniques because they create demand for clinics, equipment and drugs, are shaped by regulation and technology advances, and can drive predictable revenue growth much like a specialized service industry responding to rising customer need.
pharmacologymedical
Pharmacology is the science of how drugs affect the body and how the body affects drugs — including what a drug does, how much is needed, how long it lasts, and possible side effects. For investors, pharmacology matters because it determines whether a medicine is likely to work safely, how it will be dosed, what risks regulators and doctors will see, and therefore how big its market and approval chances might be — like testing a recipe to see if it will reliably satisfy customers.
genetically engineered model servicesmedical
A service that creates living test systems—such as cells or animals—whose genes have been deliberately altered to mimic human disease or drug responses. Think of them as custom-built crash-test dummies for biology that let researchers see how a treatment works before human trials. Investors care because these services shorten development time, lower early-stage risk, and generate steady revenues tied to drug discovery and regulatory testing demand.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
As the first commercial provider to deliver in vitro fertility services for rat models, Company demonstrates commitment to the 3Rs
WILMINGTON, Mass.--(BUSINESS WIRE)--
Charles River Laboratories today announced an enhanced In Vitro Fertility (IVF) service bundle designed to accelerate rat-model programs across therapeutics areas, including oncology, neurology, cardiology, and metabolic. By leveraging embryo transfer, cryopreservation, and colony rederivation, teams can rapidly recover lines, expand cohorts, and safeguard critical genotypes—while reducing downtime caused by breeding bottlenecks. This offering pairs dedicated project management with optional health monitoring and genetic validation to help ensure continuity across discovery, pharmacology, and translational studies. Researchers working in these therapeutic areas can request a streamlined quote and timeline starting this quarter to keep studies on track and data flowing.
“The introduction of rat IVF is an exciting step forward for Charles River, helping shorten breeding timelines and deliver more consistent, predictable outcomes while making it easier to build healthy animal colonies and keep research moving forward,” said Colin Dunn, Corporate Senior Vice President, Global Research Models & Services, Charles River. “Introducing this service provides researchers with a new avenue to advance drug development research and help bring treatment to patients faster, while maintaining industry-leading standards.”
IVF, an enhanced Assisted Reproduction Technique, is an efficient option for working with small animal groups, accelerating project timelines, and accommodating animals of any health status. By replacing natural mating, IVF saves time and reduces the number of animals required. The process fertilizes eggs outside the body, replicating natural fertilization in a laboratory environment to create embryos for implantation, genetic modification, and preservation. IVF supports the rescue of valuable lines, colony expansion, embryo production, recovery of cryopreserved models, and the maintenance of high health standards through rederivation.
“For decades, IVF has been leveraged in mouse models to accelerate research timelines,” said Matt Bouchard, Executive Director, NA Genetically Engineered Model Services, Charles River. “We are excited to now offer the same benefits in rat models due to our IVF protocol modifications, expanding options for investigators and ensuring the ideal model enters research.”
Genetically Engineered Model Services
Charles River’s Genetically Engineered Model Services (GEMS) offer a premium selection of strategic services tailored to specific needs and designed to enhance research, save time, and reduce costs. With extensive expertise in colony management, our dedicated project managers work to create customized breeding plans, address program challenges, and handle logistics to deliver study-ready model cohorts, meeting VAF/Elite ® (SOPF) health standards.
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
